BenevolentAI SPAC Presentation Deck

BEN-2293 is progressing in an adaptive Phase I/II clinical study, with full data expected in mid 2022 Part A 2 3 4 First in Human Dose Escalation 3/4 cohorts completed, data expected late 2021 Safety, Tolerability, PK 8 Mild-Moderate AD patients (18-65 years) per cohort, randomised 3:1 BEN-2293:Placebo Adaptive ascending dose cohort design Includes efficacy endpoints MALDI imaging (evaluate human skin PK) Review Late 2021 Part A efficacy readout variability and response Statistical modelling Finalise Part B design Part B Efficacy Cohort(s) Full data expected by middle of 2022 30-45 Mild-Moderate AD patients (18-65 years) per arm, final design and sample size dependent on Part A outcome Efficacy Outcome measures include itch (NRS) and inflammation (VIGA, EASI) Additional safety, tolerability and PK Biomarker panel (reflects PanTrk mechanism and AD effect) Our intention is to out-licence development and commercialisation of BEN-2293 following completion of this trial, with good interest from key Big Pharma and Dermatology specialists as potential partners Benevolent 24

View entire presentation